Experimental drug shows promise for rare melanoma type
NCT ID NCT02975700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tumors shrink or stabilize, the study was small and more research is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Samsung Medical Center
Seoul, Gangnam-Gu, 06351, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
-
Sun Yat-sen Hospital
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?